Cargando…
The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease
Levodopa (L-DOPA) treatment in Parkinson’s disease is limited by the emergence of L-DOPA-induced dyskinesia. Such dyskinesia is associated with aberrant gene regulation in neurons of the striatum, which is caused by abnormal dopamine release from serotonin terminals. Previous work showed that modula...
Autores principales: | Altwal, Feras, Moon, Connor, West, Anthony R., Steiner, Heinz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600385/ https://www.ncbi.nlm.nih.gov/pubmed/33050305 http://dx.doi.org/10.3390/cells9102265 |
Ejemplares similares
-
Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease
por: Altwal, Feras, et al.
Publicado: (2021) -
Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia
por: Fieblinger, Tim, et al.
Publicado: (2014) -
Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
por: Navailles, Sylvia, et al.
Publicado: (2012) -
Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?
por: Rylander Ottosson, Daniella, et al.
Publicado: (2016) -
Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia
por: Budrow, Carla, et al.
Publicado: (2023)